|
Statement
| 1.Date of the shareholders' meeting resolution:2022/05/24
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Director：Center Laboratories, Inc.
Director：Jung Chin Lin Representative of Center Laboratories, Inc.
Director：Wann Lai Cheng Representative of Center Laboratories, Inc.
Director：Su-Chi Wang Representative of BioEngine Technology Development Inc.
Director：De-Fu Hsieh Representative of 順晟藥品有限公司
Independent Director：Chih Yung Chin
3.Items of competitive conduct in which the officer is
permitted to engage:
The director's concurrent position in other company whose business is partly
the same or similar with the Company.
4.Period of permission to engage in the competitive conduct:
During the term of being a director of the company.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Voting results: 94,076,082 voting rights in favor, accounting for 99.91% of
the 94,155,642 voting rights of shareholders present at the time of the poll,
and the lifting of the company's director's prohibition on competition.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
Inc.
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
Director, Shanghai Bao Pharmaceutical Co., Ltd.
Director, Centergene Pharmaceuticals Co., Ltd.
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
Inc.
Director, Bioflag Co., Ltd. (Huai'an)
Director, Ausnutria Dairy (China) Co., Ltd.
Director, Hyproca Bio-science Co.,Ltd.
Director, Hyproca Nutrition Co. Ltd.
8.Address of the mainland China enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
Shanghai Bao Pharmaceutical Co., Ltd.：50 Luoxin Road, Baoshan District,
Shanghai
Centergene Pharmaceuticals Co., Ltd.：Unit 301B, C13 building, bio nano
Park,218 Xinghu street, Suzhou Industrial Park
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
Inc.
Bioflag Co., Ltd. (Huai'an): No.2, Jingyi Road, Huai'an E.D.A.
Ausnutria Dairy (China) Co., Ltd.: Floor 8, Xindaxin Building A, No.168,
Huangxing Middle Road, Changsha, Hunan, China
Hyproca Bio-science Co.,Ltd.: No.2, Wangwang East Road, Wangcheng District
Economic and Technology Development Zone, Changsha, Hunan, China
Hyproca Nutrition Co. Ltd.：Floor 21, Block B, Zuopin, No.1, No.399, Bayi
Road, Furong District, Changsha, Hunan, China
9.Operations of the mainland China enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
Shanghai Bao Pharmaceutical Co., Ltd.：Protein drug development
Centergene Pharmaceuticals Co., Ltd.：Research and development
of biopharmaceutical technology
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
Inc.
Bioflag Co., Ltd. (Huai'an): Nutritional supplements development and
production
Ausnutria Dairy (China) Co., Ltd.: Production, marketing and distribution
of dairy and related products in Mainland China
Hyproca Bio-science Co.,Ltd.: Marketing and distribution of dairy products
in Mainland China
Hyproca Nutrition Co. Ltd.: Marketing and distribution of goat milk
nutrition products in Mainland China
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:None
12.Any other matters that need to be specified:None
|
